xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05987462</url>
    </required_header>
    <id_info>
      <org_study_id>KTU-ACIN-9286</org_study_id>
      <nct_id>NCT05987462</nct_id>
    </id_info>
    <brief_title>The Effect of Green Walking on Myocardial Infarction Patients</brief_title>
    <official_title>Investigation of the Effect of Green Walking on Body Mass Index, Blood Lipids, Disease Perception, and Quality of Life in Patients With Myocardial Infarction</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>AYNUR CİN</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Karadeniz Technical University</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The study aimed to experimentally investigate the effect of green walking on body mass index,&#xD;
        blood lipids, disease perception, and quality of life in patients with MI.The study aimed to&#xD;
        experimentally investigate the effect of green walking on body mass index, blood lipids,&#xD;
        disease perception, and quality of life in patients with MI.&#xD;
  &#xD;
        Research Question 1: What is the impact of green walking on the body mass index (BMI) of&#xD;
        patients with MI? Research Question 2: How does green walking influence blood lipid levels&#xD;
        (triglycerides, LDL, total cholesterol, and HDL) in patients with MI? Research Question 3:&#xD;
        What is the effect of green walking on the perception of the disease in patients with MI?&#xD;
        Research Question 4: How does green walking affect the quality of life of patients with MI? 2&#xD;
        Groups: Green walking group and control group&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Setting and Time of the Study The data were collected in the Cardiology Outpatient Clinic of&#xD;
        X State Hospital and Y State Hospital between February and June 2022.&#xD;
  &#xD;
        Population and Sample of the Study The study population consisted of patients who were&#xD;
        receiving outpatient care at the Cardiology Outpatient Clinic of X State Hospital and Y State&#xD;
        Hospital and had experienced a myocardial infarction (MI) at least three months ago. To&#xD;
        determine the appropriate sample size, a power analysis was conducted using the G*Power&#xD;
        3.1.9.6 program based on a previous study (23) involving MI patients. The power analysis&#xD;
        resulted in a sample size of 34 patients in total, with 17 patients allocated to each group.&#xD;
        This sample size was determined to achieve 80% power, an effect size of 0.87, and a margin of&#xD;
        error of 5%. However, considering that increasing the sample size would decrease the standard&#xD;
        error and increase the study power (24), each group was increased by 75%. As a result, a&#xD;
        total of 60 patients, with 30 patients in each group, were included in the study. For&#xD;
        practical reasons (geographical location, working conditions, and limited availability of&#xD;
        myocardial infarction (MI) patients), a total of 30 MI patients who were being treated as&#xD;
        outpatients at the Cardiology Outpatient Clinic of Y State Hospital and had experienced MI at&#xD;
        least three months prior were assigned to the experimental group. Another 30 MI patients who&#xD;
        were being followed up as outpatients at the Cardiology Outpatient Clinic of X State Hospital&#xD;
        and had also experienced MI at least three months before were assigned to the control group&#xD;
        using criterion sampling. Criterion sampling involves selecting individuals based on&#xD;
        predetermined criteria or qualifications for the study's objectives. It is important to note&#xD;
        that in this study, the assignment of patients into groups was not done through randomization&#xD;
        or matching. However, statistical analyses of the descriptive and disease-related information&#xD;
        of the patients indicated no significant differences between the groups. This outcome&#xD;
        confirms that the descriptive and disease-related characteristics of the groups were similar,&#xD;
        thereby achieving an equal and homogeneous distribution in the study.&#xD;
  &#xD;
        Green Walk Group Patients who were admitted to the Cardiology Outpatient Clinic of Y State&#xD;
        Hospital and passed the six-minute walk test (6MWT) conducted by the cardiology physician&#xD;
        were eligible for participation in the green walk group. Following the physician's&#xD;
        examination at the Cardiology Outpatient Clinic, the researcher conducted face-to-face&#xD;
        interviews with the patients in a private room. During these interviews, the patients were&#xD;
        administered the Structured Patient Information Form, Blood Lipids and BMI Monitoring Form,&#xD;
        the Brief IPQ, and the MIDAS, and the collected data were recorded on the respective forms.&#xD;
        Then, the researcher provided detailed information to the patients about green walking. For&#xD;
        the randomized MI patients, two groups were formed, and they engaged in a 50-minute green&#xD;
        walking three days a week for 12 weeks, under the guidance of the researcher. The green walk&#xD;
        group's walks were scheduled differently for the two subgroups. The first subgroup had their&#xD;
        50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks&#xD;
        on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval&#xD;
        between green walks for both groups. Additionally, a follow-up Blood Lipids and BMI&#xD;
        Monitoring Form was administered to the patients during their visit to the Cardiology&#xD;
        Polyclinic in the middle of the study (6th week). At the end of the 12-week period, the&#xD;
        patients in the green walk group underwent a posttest evaluation.&#xD;
  &#xD;
        Control Group: Patients who were admitted to the Cardiology Outpatient Clinic of X State&#xD;
        Hospital and passed the 6MWT conducted by the cardiology physician were enrolled in the&#xD;
        control group. Upon their visit to the outpatient clinic, the patients in this group&#xD;
        underwent a face-to-face interview, during which they were administered the &quot;Structured&#xD;
        Patient Information Form,&quot; the &quot;Blood Lipids and BMI Monitoring Form,&quot; the &quot;Brief-IPQ,&quot; and&#xD;
        the &quot;MIDAS&quot; as pretests. The information and data collected from these interviews were&#xD;
        recorded on the respective forms. The patients in the control group continued with their&#xD;
        routine daily activities. No specific intervention or additional measures were implemented by&#xD;
        the investigator in this group. Furthermore, a follow-up &quot;Blood Lipids and BMI Monitoring&#xD;
        Form&quot; was administered to the patients during their visit to the Cardiology Outpatient Clinic&#xD;
        in the middle of the study (6th week). At the end of the 12-week period, the patients in the&#xD;
        control group underwent a posttest.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Completed</overall_status>
    <start_date type="Actual">February 1, 2022</start_date>
    <completion_date type="Actual">June 30, 2022</completion_date>
    <primary_completion_date type="Actual">April 15, 2022</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Non-Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Supportive Care</primary_purpose>
      <masking>Double (Participant, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>The Structured Patient Information Form</measure>
      <time_frame>1 day before the study</time_frame>
      <description>Developed by the researcher after reviewing the literature, the form consisted of two parts. The first part included six questions to determine the sociodemographic characteristics of the patients (gender, age, education level, marital status, employment status, and occupation), and the second part included a total of 10 questions, including four questions to determine the characteristics related to the disease (when MI occurred, presence of MI risk factors, etc.).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>The Blood Lipids and BMI Monitoring Form</measure>
      <time_frame>1 day before the study</time_frame>
      <description>This form was developed by the researcher in line with the literature. It included blood lipids (HDL, LDL, Triglyceride and Total cholesterol), height (cm), and weight (kg) measurements of the patients. BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). The blood lipid measurement results of the patients (1st-week measurement; 6th-week interim measurement; 12th-week measurement) were obtained from the patient file by the researcher during Cardiology Outpatient Clinic visits.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>The Brief Illness Perception Questionnaire (Brief IPQ)</measure>
      <time_frame>1 day before the study</time_frame>
      <description>This scale was developed by Broadbent et al. in 2006. The nine-item section of the scale defines the emotional and cognitive aspects of illness perception. Each item in the scale consists of open-ended questions and is scored between 0 and 10. In the last item, the individual is asked to indicate three factors that he/she thinks are the cause of his/her illness. These items include consequences, timeline, personal control, treatment control, identity, illness concern, coherency, and emotional response, respectively. The highest and lowest scores are 80 and 0. On the scale, the positive reaction consists of the score given to three sub-dimensions (3rd, 4th, and 7th) with a score between 0-10, and the negative reaction consists of the score given to five sub-dimensions (1st, 2nd, 5th, 6th, and 8th). Sub-dimension (1st, 2nd, 5th, 6th, and 8th) items are reverse scored. High scores indicate a negative perception of illness.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>The Myocardial Infarction Dimensional Assessment Scale (MIDAS)</measure>
      <time_frame>1 day before the study</time_frame>
      <description>The Turkish validity and reliability of the MIDAS, devised by David Thompson et al. in 2002, were examined by Uysal et al. (2008), and the Cronbach alpha value of the scale was calculated as 0.83. The scale includes 35 items and seven sub-dimensions, including physical activity, insecurity, emotional reaction, dependency, diet, concerns over medication, and side effects. The scoring of the scale is between 0 and 100. A high score on the scale indicates poor health status.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Weight</measure>
      <time_frame>1 day before the study</time_frame>
      <description>Weight was measured with a medical scale with a hospital-calibrated height scale while the patients were fasting, after removing their thick clothes and before the physician examination.Then it was recorded The Blood Lipids and BMI Monitoring Form.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Height</measure>
      <time_frame>1 day before the study</time_frame>
      <description>Height measurements were performed with the patient standing barefoot with the head in the Frankfort plane and the feet side by side in a medical basin with a height meter calibrated by the hospital.Then it was recorded The Blood Lipids and BMI Monitoring Form.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Body Mass Index</measure>
      <time_frame>1 day before the study</time_frame>
      <description>BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). Then it was recorded The Blood Lipids and BMI Monitoring Form.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Six-minute walk test</measure>
      <time_frame>1 day before the study</time_frame>
      <description>It is a widely used test to assess treatment response in moderately severe heart or lung disease or to assess functional capacity, which is a determinant of mortality and morbidity in a person with a one-time measurement (in diseases such as Alzheimer's, elderly patients, MS, Parkinson's, osteoarthritis, spinal cord injury, stroke).</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>The Blood Lipids and BMI Monitoring Form</measure>
      <time_frame>in the middle of the study (6th week).</time_frame>
      <description>This form was developed by the researcher in line with the literature. It included blood lipids (HDL, LDL, Triglyceride and Total cholesterol), height (cm), and weight (kg) measurements of the patients. BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). The blood lipid measurement results of the patients (1st-week measurement; 6th-week interim measurement; 12th-week measurement) were obtained from the patient file by the researcher during Cardiology Outpatient Clinic visits.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Weight</measure>
      <time_frame>in the middle of the study (6th week).Then it was recorded The Blood Lipids and BMI Monitoring Form.</time_frame>
      <description>Weight was measured with a medical scale with a hospital-calibrated height scale while the patients were fasting, after removing their thick clothes and before the physician examination.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Height</measure>
      <time_frame>in the middle of the study (6th week).</time_frame>
      <description>Height measurements were performed with the patient standing barefoot with the head in the Frankfort plane and the feet side by side in a medical basin with a height meter calibrated by the hospital.Then it was recorded The Blood Lipids and BMI Monitoring Form.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Body Mass Index</measure>
      <time_frame>in the middle of the study (6th week).</time_frame>
      <description>BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). Then it was recorded The Blood Lipids and BMI Monitoring Form.</description>
    </secondary_outcome>
    <other_outcome>
      <measure>The Blood Lipids and BMI Monitoring Form</measure>
      <time_frame>At the end of the 12-week period</time_frame>
      <description>This form was developed by the researcher in line with the literature. It included blood lipids (HDL, LDL, Triglyceride and Total cholesterol), height (cm), and weight (kg) measurements of the patients. BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). The blood lipid measurement results of the patients (1st-week measurement; 6th-week interim measurement; 12th-week measurement) were obtained from the patient file by the researcher during Cardiology Outpatient Clinic visits.</description>
    </other_outcome>
    <other_outcome>
      <measure>The Brief Illness Perception Questionnaire (Brief IPQ)</measure>
      <time_frame>At the end of the 12-week period</time_frame>
      <description>This scale was developed by Broadbent et al. in 2006. The nine-item section of the scale defines the emotional and cognitive aspects of illness perception. Each item in the scale consists of open-ended questions and is scored between 0 and 10. In the last item, the individual is asked to indicate three factors that he/she thinks are the cause of his/her illness. These items include consequences, timeline, personal control, treatment control, identity, illness concern, coherency, and emotional response, respectively. The highest and lowest scores are 80 and 0. On the scale, the positive reaction consists of the score given to three sub-dimensions (3rd, 4th, and 7th) with a score between 0-10, and the negative reaction consists of the score given to five sub-dimensions (1st, 2nd, 5th, 6th, and 8th). Sub-dimension (1st, 2nd, 5th, 6th, and 8th) items are reverse scored. High scores indicate a negative perception of illness.</description>
    </other_outcome>
    <other_outcome>
      <measure>The Myocardial Infarction Dimensional Assessment Scale (MIDAS)</measure>
      <time_frame>At the end of the 12-week period</time_frame>
      <description>The Turkish validity and reliability of the MIDAS, devised by David Thompson et al. in 2002, were examined by Uysal et al. (2008), and the Cronbach alpha value of the scale was calculated as 0.83. The scale includes 35 items and seven sub-dimensions, including physical activity, insecurity, emotional reaction, dependency, diet, concerns over medication, and side effects. The scoring of the scale is between 0 and 100. A high score on the scale indicates poor health status.</description>
    </other_outcome>
    <other_outcome>
      <measure>Weight</measure>
      <time_frame>At the end of the 12-week period</time_frame>
      <description>Weight was measured with a medical scale with a hospital-calibrated height scale while the patients were fasting, after removing their thick clothes and before the physician examination.Then it was recorded The Blood Lipids and BMI Monitoring Form.</description>
    </other_outcome>
    <other_outcome>
      <measure>Height</measure>
      <time_frame>At the end of the 12-week period</time_frame>
      <description>Height measurements were performed with the patient standing barefoot with the head in the Frankfort plane and the feet side by side in a medical basin with a height meter calibrated by the hospital.Then it was recorded The Blood Lipids and BMI Monitoring Form.</description>
    </other_outcome>
    <other_outcome>
      <measure>Body Mass Index</measure>
      <time_frame>At the end of the 12-week period</time_frame>
      <description>MI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). Then it was recorded The Blood Lipids and BMI Monitoring Form.</description>
    </other_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Actual">60</enrollment>
    <condition>Myocardial Infarction</condition>
    <condition>Quality of Life</condition>
    <arm_group>
      <arm_group_label>Green Walk group</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Patients who were admitted to the Cardiology Outpatient Clinic of Y State Hospital and passed the 6MWT conducted by the cardiology physician were eligible for participation in the green walk group. Following the physician's examination at the Cardiology Outpatient Clinic, the researcher conducted face-to-face interviews with the patients in a private room. During these interviews, the patients were administered the Structured Patient Information Form, Blood Lipids and BMI Monitoring Form, the Brief IPQ, and the MIDAS, and the collected data were recorded on the respective forms. Then, the researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Control group</arm_group_label>
      <arm_group_type>No Intervention</arm_group_type>
      <description>Patients who were admitted to the Cardiology Outpatient Clinic of X State Hospital and passed the 6MWT conducted by the cardiology physician were enrolled in the control group. Upon their visit to the outpatient clinic, the patients in this group underwent a face-to-face interview, during which they were administered the &quot;Structured Patient Information Form,&quot; the &quot;Blood Lipids and BMI Monitoring Form,&quot; the &quot;Brief-IPQ,&quot; and the &quot;MIDAS&quot; as pretests. . The patients in the control group continued with their routine daily activities. No specific intervention or additional measures were implemented by the investigator in this group. Furthermore, a follow-up &quot;Blood Lipids and BMI Monitoring Form&quot; was administered to the patients during their visit to the Cardiology Outpatient Clinic in the middle of the study (6th week). At the end of the 12-week period, the patients in the control group underwent a posttest.</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Green walking</intervention_name>
      <description>The researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups. The first subgroup had their 50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval between green walks for both groups.</description>
      <arm_group_label>Green Walk group</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Inclusion criteria were being 18 years of age or older,&#xD;
  &#xD;
            -  being able to communicate verbally,&#xD;
  &#xD;
            -  being literate,&#xD;
  &#xD;
            -  having had MI at least three months ago,&#xD;
  &#xD;
            -  being followed up as an outpatient with the diagnosis of MI in the cardiology&#xD;
               outpatient clinic of X state hospital and Y state hospital,&#xD;
  &#xD;
            -  achieving the six-minute walk test (6MWT),&#xD;
  &#xD;
            -  having no obstacle to walking (musculoskeletal problems, joint problems, fracture,&#xD;
               neuropathy, chronic severe pain, limb loss)&#xD;
  &#xD;
            -  volunteering to participate in the study.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  having blood pressure above 140/90 mmHg or below 90/60 mmHg,&#xD;
  &#xD;
            -  having active chest pain, dyspnea, bradycardia, or tachycardia, a psychiatric&#xD;
               diagnosis, visual, hearing,&#xD;
  &#xD;
            -  cognitive impairment,&#xD;
  &#xD;
            -  a balance problem,&#xD;
  &#xD;
            -  using a walker while walking,&#xD;
  &#xD;
            -  having Parkinson's disease, dementia, or cancer,&#xD;
  &#xD;
            -  having undergone any surgery that would prevent walking,&#xD;
  &#xD;
            -  refusing to participate in the study.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>85 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <location>
      <facility>
        <name>Gümüşhane State Hospital and Gümüşhane Kelkit State Hospital</name>
        <address>
          <city>Gümüşhane</city>
          <zip>29000</zip>
          <country>Turkey</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>Turkey</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>July 2, 2023</study_first_submitted>
    <study_first_submitted_qc>August 3, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 14, 2023</study_first_posted>
    <last_update_submitted>August 3, 2023</last_update_submitted>
    <last_update_submitted_qc>August 3, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 14, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor-Investigator</responsible_party_type>
      <investigator_affiliation>Karadeniz Technical University</investigator_affiliation>
      <investigator_full_name>AYNUR CİN</investigator_full_name>
      <investigator_title>ASISTANT LECTURER DR</investigator_title>
    </responsible_party>
    <keyword>Disease</keyword>
    <keyword>Nature</keyword>
    <keyword>Perception</keyword>
    <keyword>Quality of Life</keyword>
    <keyword>Green Walking</keyword>
    <keyword>Myocardial Infarction</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Myocardial Infarction</mesh_term>
      <mesh_term>Infarction</mesh_term>
    </condition_browse>
    <provided_document_section>
      <provided_document>
        <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
        <document_has_protocol>Yes</document_has_protocol>
        <document_has_icf>Yes</document_has_icf>
        <document_has_sap>Yes</document_has_sap>
        <document_date>March 17, 2021</document_date>
        <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT05987462/Prot_SAP_ICF_000.pdf</document_url>
      </provided_document>
    </provided_document_section>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05987462
  org study id: KTU-ACIN-9286
  nct id: NCT05987462
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  The study aimed to experimentally investigate the effect of green walking on body mass index,
        blood lipids, disease perception, and quality of life in patients with MI.The study aimed to
        experimentally investigate the effect of green walking on body mass index, blood lipids,
        disease perception, and quality of life in patients with MI.
  
        Research Question 1: What is the impact of green walking on the body mass index (BMI) of
        patients with MI? Research Question 2: How does green walking influence blood lipid levels
        (triglycerides, LDL, total cholesterol, and HDL) in patients with MI? Research Question 3:
        What is the effect of green walking on the perception of the disease in patients with MI?
        Research Question 4: How does green walking affect the quality of life of patients with MI? 2
        Groups: Green walking group and control group
  Setting and Time of the Study The data were collected in the Cardiology Outpatient Clinic of
        X State Hospital and Y State Hospital between February and June 2022.
  
        Population and Sample of the Study The study population consisted of patients who were
        receiving outpatient care at the Cardiology Outpatient Clinic of X State Hospital and Y State
        Hospital and had experienced a myocardial infarction (MI) at least three months ago. To
        determine the appropriate sample size, a power analysis was conducted using the G*Power
        3.1.9.6 program based on a previous study (23) involving MI patients. The power analysis
        resulted in a sample size of 34 patients in total, with 17 patients allocated to each group.
        This sample size was determined to achieve 80% power, an effect size of 0.87, and a margin of
        error of 5%. However, considering that increasing the sample size would decrease the standard
        error and increase the study power (24), each group was increased by 75%. As a result, a
        total of 60 patients, with 30 patients in each group, were included in the study. For
        practical reasons (geographical location, working conditions, and limited availability of
        myocardial infarction (MI) patients), a total of 30 MI patients who were being treated as
        outpatients at the Cardiology Outpatient Clinic of Y State Hospital and had experienced MI at
        least three months prior were assigned to the experimental group. Another 30 MI patients who
        were being followed up as outpatients at the Cardiology Outpatient Clinic of X State Hospital
        and had also experienced MI at least three months before were assigned to the control group
        using criterion sampling. Criterion sampling involves selecting individuals based on
        predetermined criteria or qualifications for the study's objectives. It is important to note
        that in this study, the assignment of patients into groups was not done through randomization
        or matching. However, statistical analyses of the descriptive and disease-related information
        of the patients indicated no significant differences between the groups. This outcome
        confirms that the descriptive and disease-related characteristics of the groups were similar,
        thereby achieving an equal and homogeneous distribution in the study.
  
        Green Walk Group Patients who were admitted to the Cardiology Outpatient Clinic of Y State
        Hospital and passed the six-minute walk test (6MWT) conducted by the cardiology physician
        were eligible for participation in the green walk group. Following the physician's
        examination at the Cardiology Outpatient Clinic, the researcher conducted face-to-face
        interviews with the patients in a private room. During these interviews, the patients were
        administered the Structured Patient Information Form, Blood Lipids and BMI Monitoring Form,
        the Brief IPQ, and the MIDAS, and the collected data were recorded on the respective forms.
        Then, the researcher provided detailed information to the patients about green walking. For
        the randomized MI patients, two groups were formed, and they engaged in a 50-minute green
        walking three days a week for 12 weeks, under the guidance of the researcher. The green walk
        group's walks were scheduled differently for the two subgroups. The first subgroup had their
        50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks
        on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval
        between green walks for both groups. Additionally, a follow-up Blood Lipids and BMI
        Monitoring Form was administered to the patients during their visit to the Cardiology
        Polyclinic in the middle of the study (6th week). At the end of the 12-week period, the
        patients in the green walk group underwent a posttest evaluation.
  
        Control Group: Patients who were admitted to the Cardiology Outpatient Clinic of X State
        Hospital and passed the 6MWT conducted by the cardiology physician were enrolled in the
        control group. Upon their visit to the outpatient clinic, the patients in this group
        underwent a face-to-face interview, during which they were administered the "Structured
        Patient Information Form," the "Blood Lipids and BMI Monitoring Form," the "Brief-IPQ," and
        the "MIDAS" as pretests. The information and data collected from these interviews were
        recorded on the respective forms. The patients in the control group continued with their
        routine daily activities. No specific intervention or additional measures were implemented by
        the investigator in this group. Furthermore, a follow-up "Blood Lipids and BMI Monitoring
        Form" was administered to the patients during their visit to the Cardiology Outpatient Clinic
        in the middle of the study (6th week). At the end of the 12-week period, the patients in the
        control group underwent a posttest.
  allocation: Non-Randomized
  intervention model: Parallel Assignment
  primary purpose: Supportive Care
  masking: Double (Participant, Outcomes Assessor)
  measure: The Structured Patient Information Form
  time frame: 1 day before the study
  description: Developed by the researcher after reviewing the literature, the form consisted of two parts. The first part included six questions to determine the sociodemographic characteristics of the patients (gender, age, education level, marital status, employment status, and occupation), and the second part included a total of 10 questions, including four questions to determine the characteristics related to the disease (when MI occurred, presence of MI risk factors, etc.).
  measure: The Blood Lipids and BMI Monitoring Form
  time frame: 1 day before the study
  description: This form was developed by the researcher in line with the literature. It included blood lipids (HDL, LDL, Triglyceride and Total cholesterol), height (cm), and weight (kg) measurements of the patients. BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). The blood lipid measurement results of the patients (1st-week measurement; 6th-week interim measurement; 12th-week measurement) were obtained from the patient file by the researcher during Cardiology Outpatient Clinic visits.
  measure: The Brief Illness Perception Questionnaire (Brief IPQ)
  time frame: 1 day before the study
  description: This scale was developed by Broadbent et al. in 2006. The nine-item section of the scale defines the emotional and cognitive aspects of illness perception. Each item in the scale consists of open-ended questions and is scored between 0 and 10. In the last item, the individual is asked to indicate three factors that he/she thinks are the cause of his/her illness. These items include consequences, timeline, personal control, treatment control, identity, illness concern, coherency, and emotional response, respectively. The highest and lowest scores are 80 and 0. On the scale, the positive reaction consists of the score given to three sub-dimensions (3rd, 4th, and 7th) with a score between 0-10, and the negative reaction consists of the score given to five sub-dimensions (1st, 2nd, 5th, 6th, and 8th). Sub-dimension (1st, 2nd, 5th, 6th, and 8th) items are reverse scored. High scores indicate a negative perception of illness.
  measure: The Myocardial Infarction Dimensional Assessment Scale (MIDAS)
  time frame: 1 day before the study
  description: The Turkish validity and reliability of the MIDAS, devised by David Thompson et al. in 2002, were examined by Uysal et al. (2008), and the Cronbach alpha value of the scale was calculated as 0.83. The scale includes 35 items and seven sub-dimensions, including physical activity, insecurity, emotional reaction, dependency, diet, concerns over medication, and side effects. The scoring of the scale is between 0 and 100. A high score on the scale indicates poor health status.
  measure: Weight
  time frame: 1 day before the study
  description: Weight was measured with a medical scale with a hospital-calibrated height scale while the patients were fasting, after removing their thick clothes and before the physician examination.Then it was recorded The Blood Lipids and BMI Monitoring Form.
  measure: Height
  time frame: 1 day before the study
  description: Height measurements were performed with the patient standing barefoot with the head in the Frankfort plane and the feet side by side in a medical basin with a height meter calibrated by the hospital.Then it was recorded The Blood Lipids and BMI Monitoring Form.
  measure: Body Mass Index
  time frame: 1 day before the study
  description: BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). Then it was recorded The Blood Lipids and BMI Monitoring Form.
  measure: Six-minute walk test
  time frame: 1 day before the study
  description: It is a widely used test to assess treatment response in moderately severe heart or lung disease or to assess functional capacity, which is a determinant of mortality and morbidity in a person with a one-time measurement (in diseases such as Alzheimer's, elderly patients, MS, Parkinson's, osteoarthritis, spinal cord injury, stroke).
  measure: The Blood Lipids and BMI Monitoring Form
  time frame: in the middle of the study (6th week).
  description: This form was developed by the researcher in line with the literature. It included blood lipids (HDL, LDL, Triglyceride and Total cholesterol), height (cm), and weight (kg) measurements of the patients. BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). The blood lipid measurement results of the patients (1st-week measurement; 6th-week interim measurement; 12th-week measurement) were obtained from the patient file by the researcher during Cardiology Outpatient Clinic visits.
  measure: Weight
  time frame: in the middle of the study (6th week).Then it was recorded The Blood Lipids and BMI Monitoring Form.
  description: Weight was measured with a medical scale with a hospital-calibrated height scale while the patients were fasting, after removing their thick clothes and before the physician examination.
  measure: Height
  time frame: in the middle of the study (6th week).
  description: Height measurements were performed with the patient standing barefoot with the head in the Frankfort plane and the feet side by side in a medical basin with a height meter calibrated by the hospital.Then it was recorded The Blood Lipids and BMI Monitoring Form.
  measure: Body Mass Index
  time frame: in the middle of the study (6th week).
  description: BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). Then it was recorded The Blood Lipids and BMI Monitoring Form.
  measure: The Blood Lipids and BMI Monitoring Form
  time frame: At the end of the 12-week period
  description: This form was developed by the researcher in line with the literature. It included blood lipids (HDL, LDL, Triglyceride and Total cholesterol), height (cm), and weight (kg) measurements of the patients. BMI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). The blood lipid measurement results of the patients (1st-week measurement; 6th-week interim measurement; 12th-week measurement) were obtained from the patient file by the researcher during Cardiology Outpatient Clinic visits.
  measure: The Brief Illness Perception Questionnaire (Brief IPQ)
  time frame: At the end of the 12-week period
  description: This scale was developed by Broadbent et al. in 2006. The nine-item section of the scale defines the emotional and cognitive aspects of illness perception. Each item in the scale consists of open-ended questions and is scored between 0 and 10. In the last item, the individual is asked to indicate three factors that he/she thinks are the cause of his/her illness. These items include consequences, timeline, personal control, treatment control, identity, illness concern, coherency, and emotional response, respectively. The highest and lowest scores are 80 and 0. On the scale, the positive reaction consists of the score given to three sub-dimensions (3rd, 4th, and 7th) with a score between 0-10, and the negative reaction consists of the score given to five sub-dimensions (1st, 2nd, 5th, 6th, and 8th). Sub-dimension (1st, 2nd, 5th, 6th, and 8th) items are reverse scored. High scores indicate a negative perception of illness.
  measure: The Myocardial Infarction Dimensional Assessment Scale (MIDAS)
  time frame: At the end of the 12-week period
  description: The Turkish validity and reliability of the MIDAS, devised by David Thompson et al. in 2002, were examined by Uysal et al. (2008), and the Cronbach alpha value of the scale was calculated as 0.83. The scale includes 35 items and seven sub-dimensions, including physical activity, insecurity, emotional reaction, dependency, diet, concerns over medication, and side effects. The scoring of the scale is between 0 and 100. A high score on the scale indicates poor health status.
  measure: Weight
  time frame: At the end of the 12-week period
  description: Weight was measured with a medical scale with a hospital-calibrated height scale while the patients were fasting, after removing their thick clothes and before the physician examination.Then it was recorded The Blood Lipids and BMI Monitoring Form.
  measure: Height
  time frame: At the end of the 12-week period
  description: Height measurements were performed with the patient standing barefoot with the head in the Frankfort plane and the feet side by side in a medical basin with a height meter calibrated by the hospital.Then it was recorded The Blood Lipids and BMI Monitoring Form.
  measure: Body Mass Index
  time frame: At the end of the 12-week period
  description: MI was calculated by dividing body weight by the square meter of height (BMI=kg/m2). Then it was recorded The Blood Lipids and BMI Monitoring Form.
  arm group label: Green Walk group
  arm group type: Experimental
  description: Patients who were admitted to the Cardiology Outpatient Clinic of Y State Hospital and passed the 6MWT conducted by the cardiology physician were eligible for participation in the green walk group. Following the physician's examination at the Cardiology Outpatient Clinic, the researcher conducted face-to-face interviews with the patients in a private room. During these interviews, the patients were administered the Structured Patient Information Form, Blood Lipids and BMI Monitoring Form, the Brief IPQ, and the MIDAS, and the collected data were recorded on the respective forms. Then, the researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups.
  arm group label: Control group
  arm group type: No Intervention
  description: Patients who were admitted to the Cardiology Outpatient Clinic of X State Hospital and passed the 6MWT conducted by the cardiology physician were enrolled in the control group. Upon their visit to the outpatient clinic, the patients in this group underwent a face-to-face interview, during which they were administered the "Structured Patient Information Form," the "Blood Lipids and BMI Monitoring Form," the "Brief-IPQ," and the "MIDAS" as pretests. . The patients in the control group continued with their routine daily activities. No specific intervention or additional measures were implemented by the investigator in this group. Furthermore, a follow-up "Blood Lipids and BMI Monitoring Form" was administered to the patients during their visit to the Cardiology Outpatient Clinic in the middle of the study (6th week). At the end of the 12-week period, the patients in the control group underwent a posttest.
  intervention type: Other
  intervention name: Green walking
  description: The researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups. The first subgroup had their 50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval between green walks for both groups.
  arm group label: Green Walk group
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 85 Years
  healthy volunteers: No
  facility: 
  country: Turkey
  responsible party type: Sponsor-Investigator
  investigator affiliation: Karadeniz Technical University
  investigator full name: AYNUR CİN
  investigator title: ASISTANT LECTURER DR
  mesh term: Myocardial Infarction
  mesh term: Infarction
  provided document: 